NRG Oncology Clinical Trial: NRG-LU007

Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial

About the trial

NRG-LU007 is a clinical study for people with extensive stage small cell lung cancer (SCLC) that is testing if adding radiation therapy to the usual treatment can extend the time without your cancer growing or spreading. Typically, people with extensive stage SCLC are treated initially with chemotherapy and the immune therapy drug, atezolizumab, followed by atezolizumab alone after chemotherapy is complete. NRG-LU007 is designed to determine if adding radiation therapy to atezolizumab after chemotherapy could improve survival outcomes for people with this type of lung cancer. Previous studies involving extensive stage SCLC patients have shown that adding radiation therapy to immune therapy is safe and have shown benefit. This trial is also known as the “RAPTOR” trial.

Can adding radiation to immune therapy help improve survival for people with extensive stage small cell lung cancer?

About NRG Oncology

As one of the five research groups in the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), NRG Oncology carries out clinical trials on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types.

NRG Oncology’s extensive research organization includes investigators, medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians. The NRG Oncology includes more than 1,300 research sites worldwide, primarily in the United States and Canada. NRG Oncology is a non-profit research organization, funded mainly through grants from the NCI.

To contact NRG Oncology, call 267-519-6630 or email info@nrgoncology.org.
What is a clinical trial?
Clinical trials are research studies that look to find better ways to prevent, diagnose, or treat disease.

Who can join this study?
Men and women ages 18 and older who have been diagnosed with extensive stage small cell lung cancer currently being treated with a combination of the immune therapy drug atezolizumab and chemotherapy.

Can I change my mind if I choose to take part in this study?
Yes. Taking part in this study is voluntary. If you choose to participate in this study, you are able to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.

What are the possible study treatments?
If you decide to take part in the study, you will be assigned by chance to one of two treatment groups. Patients in both treatment groups will receive the immune therapy drug atezolizumab. Patients assigned to group one will only receive atezolizumab. Patients assigned to group two will receive radiation therapy in addition to the atezolizumab.

How long will I be in this study?
Patients in both treatment groups will receive the immune therapy drug atezolizumab every 3 weeks, beginning within 21 days after their last dose of atezolizumab and chemotherapy received prior to the study. Patients assigned to group one will receive only the atezolizumab. Patients assigned to group two will also receive radiation therapy once a day (Monday-Friday) during the first 5 weeks of receiving atezolizumab.

Patients in both treatment groups will continue to receive atezolizumab until their disease gets worse or their doctor stops the treatment. Patients will continue to be followed on trial to assess outcome.

Are there side effects?
There may be some. Some of the most common side effects of the immune therapy drug atezolizumab used in this study include tiredness or infection. Radiation therapy to your lungs may cause swelling or redness, numbness, or peeling of skin at the area of radiation, difficulty or pain with swallowing, hair loss at the area of radiation, shortness of breath, cough, tiredness, anemia, infection, bleeding, or bruising. Your doctor will review all of the potential side effects with you.

More Information
Visit the National Cancer Institute website at https://www.cancer.gov for more information about studies or general information about cancer. You may also call: 1-(800)-4-CANCER (1-800-422-6237).